Agomab: Piper Sandler Sees 368% Upside on Ontunisertib for Fibrostenotic Crohn’s
Agomab trades at a deep discount to Sarepta and Abivax. Piper Sandler starts at Overweight with $60 PT.
/ 13 items
#ABVX↓
Abivax Gets Positive FDA Feedback, Stays on Track to File for New Ulcerative Colitis Drug by End of 2026
Abivax completes positive pre-NDA meeting with FDA for obefazimod in ulcerative colitis, stays on track for 2026 filing, with $3-5B peak sales potential.
Oppenheimer Initiates Outperform Coverage on Palisade Bio with $8 Price Target
Strong bullish case for its oral IBD therapy ahead of Phase 2 data.
Abivax Re-Engages Centerview as It Eyes Major Pharma Partnerships After $874M Raise
Abivax has resumed partnership talks with major pharma companies via Centerview Partners while preparing a potential independent U.S. launch of obefazimod.
Abivax Shares Surge as Obefazimod Delivers Strong Phase 3 Results in Difficult-to-Treat Ulcerative Colitis
Abivax advances toward Q4 2026 NDA filing with encouraging remission and safety results.
Cancer Cases Cloud Abivax’s Landmark Phase 3 Win in Ulcerative Colitis
Abivax ulcerative colitis drug showed strong results, but cancer cases raised safety worries, sending shares down sharply.